TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male patient over 18 years old~* patient with indication for radical prostatectomy~* patient with a rectal palpable nodule or targeted MRI positive biopsies or with at least 4 positive biopsies in a hemi-prostate.~  * patient affiliated to French social security system or equivalent~ * patient who have signed a non-opposition form~Exclusion Criteria:~* patient with contraindication to radical prostatectomy~* patient with remedial prostatectomy~* patient with normal preoperative MRI or with absence of tumoral area~* patient with history of hormonal therapy~* person deprived of freedom by judicial or administrative decision~* person under legal protection~* person hospitalized for psychiatric care.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: fluorescence assessment (Type: None): Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inborn and outborn infants of 29 0/7 to 33 6/7 weeks gestational age at birth~* admitted to hospitals of the NICHD NRN who, are at time of enrollment:~* ≤35 6/7 weeks post-menstrual age at the time of randomization~* Receiving caffeine with plan to discontinue treatment or just discontinued caffeine treatment~* Receiving feeds at a volume of ≥120 ml/kg/day by oral and/or tube feeding~* Ability to start study medication within 72 hours after stopping caffeine~Exclusion Criteria:~* On respiratory therapy (oxygen more than room air equivalent for high altitude sites, nasal cannula, continuous positive pressure ventilation, and/or mechanical ventilation)~* Infants who would otherwise be discharged home on apnea monitor due to underlying disease or family history, including history of a sibling with sudden infant death syndrome~* Parental request for apnea monitor~* Congenital heart disease other than atrial septal defect, ventricular septal defect, or patent ductus arteriosus~* Neuromuscular conditions affecting respiration~* Major congenital malformation and/or genetic disorder~* Plans to transfer to a non-NRN site before discharge~* Unable to obtain parental or guardian consent

- Gender: ALL
- Minimum Age: 29 Weeks
- Maximum Age: 33 Weeks
- Healthy Volunteers: f

Study Arms:
- Caffeine Citrate (Type: EXPERIMENTAL): Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have chemotherapy-resistant acute leukemia (primary refractory or relapsed and refractory AML, ALL, undifferentiated, bi-lineage or mixed lineage leukemia)~* Participant must have a well HLA matched related, mismatched related or unrelated marrow donor with whom the patient is allele matched at at least 7 of 8 HLA loci or a single unrelated cord blood unit matched at at least 4 of 6 HLA loci with minimal dose of 4x10(7)NC/Kg~Exclusion Criteria:~* Prior allogeneic or autologous hematopoietic stem cell transplantation~* Prior exposure to AMD3100~* Active central nervous system leukemia~* Uncontrolled viral, bacterial, fungal, protozoal infection~* HIV infection~* Does not meet standard organ function for transplant

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- bone marrow transplant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with \>= 18 years of age~* Intact skin in the area of topical treatment~* Patients suffering from moderate to severe ( 5 or more points on an 11 point Numerical Rating Scale where 10 is the worst possible pain, and 0 indicates no pain) chronic daily postoperative neuropathic pain for the past 6 to 24 months.~* Patients should have symptoms for example allodynia (a pain due to a stimulus which does not normally provoke pain); and or dysesthesia (unpleasant, abnormal sense of touch).~Exclusion Criteria:~* Contraindications to lidocaine 5% medicated plaster, or paracetamol~* Evidence or history of alcohol, medication or drug abuse and/or dependency in the past 3 years.~* Evidence or history (during the past 3 years) of epilepsy, neurotic personality, psychiatric illness, or suicide risk.~* Pregnant or breastfeeding women~* Women of childbearing potential who are sexually active without satisfactory contraception for at least 28 days prior to enrollment, during the trial, and until 28 days after the follow-up visit.~* Severe renal, hepatic or heart disorder.~* Surgery in the past 3 months before screening.~* Anticipated need for surgery during the trial, requiring at least regional or general anesthesia.~* Pending litigation due to chronic pain or disability.~* Participation in another trial of investigational medicinal products or devices parallel to or less than 1 month before entry into the trial, or previous participation in this trial.~* Presence of other severe pain that could confound the assessment or self- evaluation of the localized postoperative neuropathic pain.~* For patients with chronic postoperative neuropathic pain related to a surgery due to tumors: suspected residual tumor or metastases, chemotherapy or radiotherapy for treatment of tumor(s).~* Total anesthesia in the area of localized chronic pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Plaster (Type: PLACEBO_COMPARATOR): Active Comparator
- Lidocaine Plaster (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age upon entry into screening.~* Documented history of migraine with or without aura according to the IHS ICHD-III for greater than or equal to 12 months~* Has EM defined as history of greater than or equal to 4 and less than 15 migraine days and less than 15 headache days per month on average during the 3 months prior to initial screening~* Employed greater than or equal to 20 hours/week upon entry into initial screening, stable for at least 3 months in the same job and has not specified willful termination of employment throughout the duration of the study. Employment is defined by work outside the home, self-employed, or works from home~* Has greater than or equal to 4 hours of lost productive time due to headache/migraine and/or related symptoms in the past month prior to initial screening as determined by subject~* Has total disability score of greater than 10 as assessed by MIDAS (3-month recall) at initial screening~* History of treatment failure with at least 1 preventive treatment category for migraine~Exclusion Criteria:~* Older than 50 years of age at migraine onset~* History of cluster headache, hemiplegic migraine, or other trigeminal autonomic cephalalgia.~* Taken an opioid and/or opioid-containing analgesic greater than or equal to 4 days during the 1 month prior to screening for any indication~* Taken a butalbital and/or butalbital-containing analgesic greater than or equal to 4 days during the 1 month prior to screening for any indication~* Change in the regimen of current migraine preventive treatment or a concomitant medication that may have migraine prevention effects during baseline~* Taken an opioid and/or opioid-containing analgesic ≥ 4 days during baseline for any indication.~* Taken a butalbital and/or butalbital-containing analgesic ≥ 4 days during baseline for any indication.~* Previously treated with any agent (monoclonal antibody or small molecule) targeting the CGRP pathway (ligand or receptor) in preventive settings~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
- Erenumab (Type: EXPERIMENTAL): After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Occlusive Dressing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult~* Fingertips traumatic amputations (zone 2 or 3)~Exclusion Criteria:~* Fingertips traumatic amputations (zone 1 or 4)~* Fingertips amputations non traumatic~* Traumatic history on the finger,, nervous traumatism or nerve tumor on the same upper limb~* Nervous tumor history or cervical spine traumatism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Occlusive Dressing (Type: EXPERIMENTAL): None
- Surgery (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part 1 and 2:~* Healthy adult male and female subjects between the ages of 21-55 years inclusive.~* Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum of 72 hours after each dose.~Part 3:~* RA male and female subjects between the ages of 21-70 years inclusive~* Evidence of active RA disease~* Inadequate response to biologic or non-biologic DMARDs~* Subjects will be required to be on background therapy with methotrexate.~Exclusion Criteria:~Parts 1, 2 and 3:~* BMI \<18 or \>32 kg/m2~* Clinically significant findings in physical exams and laboratory tests at screening and/or baseline~* Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU confinement, as applicable, and for 48 hours prior to study visits.~* Unwilling to abstain from exercise more strenuous than walking during CRU confinement, as applicable, and for 48 hours prior to study visits.~Parts 1 and 2:~* Use of any prescription, non-prescription, or herbal medications as well as supplements or vitamins within 4 weeks prior to dosing, unless approved by the Investigator.~* Smoking more than 10 cigarettes, or the equivalent, per day.~Part 3:~* Current or previous history of inflammatory joint disease other than RA~* Evidence of extra-articular RA disease or systemic involvement~* Currently taking any medications other than those allowed per protocol guidelines~* Any surgical procedure including bone or joint surgery within 12 weeks prior to dosing~* Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA~* Neuropathies and neurovasculopathies~* Concomitant use of statins while on study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1-FPA008/Placebo Randomize DoseLevels1-4 (Type: EXPERIMENTAL): Single infusion at 4 different dose levels
- 2-FPA008/Placebo Randomize DoseLevels1-2 (Type: EXPERIMENTAL): Dual Infusions at 2 different dose levels
- 3-FPA008 Open-Label DoseLevels 1-3 (Type: EXPERIMENTAL): Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Determine the Feasibility and Effectiveness of Early Multisensory Stimulation Intervention in Patients in the Trauma-Neurosurgical Intensive Care Unit (TNICU) Following Severe Acquired Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 2 weeks post injury, no more than 8 weeks post injury~* Glasgow Coma Scale score of less than or equal to 9, or motor component score of 5 or less if patient intubated~* No previous brain injury~* No chronic/progressive neurological illness~* No intracranial pressure monitor~* No more than1 pre-existing sensory impairment (e.g. deafness, blindness)~* Functional level of English for patient and Substitute Decision Maker (i.e. conversational English, work/education in English, completion of English as a Second Language course, etc.)~* Deemed medically appropriate as per Nurse Practitioner/MD (e.g. no active seizures, no sedation, haemodynamically stable, etc.)~Exclusion Criteria: Patients who do not meet inclusion criteria above.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multisensory Stimulation Group (Type: ACTIVE_COMPARATOR): Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
- Control Group (Type: PLACEBO_COMPARATOR): Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years old~* Patient has clinical manifestations (i.e. symptoms and/or signs) of chronic DVT of an extremity. The Venous Clinical Severity Score (VCSS) will be used to determine if the patient is currently suffering from chronic DVT, with a VCSS score of 4 or greater necessary for inclusion.~* Imaging confirmation of venous occlusion or stenosis (\>50%) involving the femoral, and/or popliteal veins~* Obstructed vessel caliber can accommodate a 7FR System, from insertion site to target segment~* Patient is able to read and answer a questionnaire in English~Exclusion Criteria:~* History of life-threatening reaction to contrast material~* Unwilling or unable to provide informed consent, or return for required follow-up evaluations~* Participating in another investigational study that has not completed follow-up testing~* Cannot receive outpatient anticoagulation such as LMWH and/or vitamin K antagonists (VKAs)~* Absolute contraindication to contrast media or renal insufficiency (baseline creatinine \>2.0 mg/dL).~* Either a history or presence of heparin-induced thrombocytopenia antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Venous Stent Arm (Type: EXPERIMENTAL): The study is a single treatment arm study and the venous stent will be placed in all eligible participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Virus Detection Project, Intervention With GAD-alum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed classical type-1 diabetes~* Positive GAD antibodies~* Fasting C-peptide \>0.1 mmol/l~* Insulin dosage \>0.1 U/kg Bodyweight/day~Exclusion Criteria:~* Pregnancy~* Weaning~* Other chronic diseases than diabetes~* Any regular medication except oral contraceptives~* Psychiatric disturbances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- GAD-alum (Type: EXPERIMENTAL): GAD-alum administered at 0 and 1 months after inclusion
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Serial BNP Testing for Heart Failure Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects must be diagnosed with heart failure and have an abnormal BNP reading.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BNP Open (Type: None): Subjects treated based on clinical assessment and knowledge of BNP values
- Control (Type: None): Subjects treated based on clinical assessment alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* over 20 years old~* patients with triple negative breast cancer diagnosed Seoul National University Hospital~* patients who decided to perform neoadjuvant chemotherapy under clinical judgement~Exclusion Criteria:~* not applicable

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- metaplastic breast cancer (Type: None): Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer.
- non-metaplastic breast cancer (Type: None): Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues